The Patent Finder

Kumho HT, Inc.

6 patents currently held · Updated Nov 20, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 12, 2027
    The maintenance fee for Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent (US 10,472,418) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Aug 20, 2027
    The maintenance fee for Antibody binding specifically to CD40 and use thereof (US 11,905,331) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,900,586Antibody That Binds Domain 2 of ICAM-1 and Methods of Treatment
In force
 · High confidence
In forceHigh confidence
US 10,472,418Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
In force
 · USPTO record
In forceUSPTO record
US 11,220,543Antibody binding specifically to CD66c and use thereof
In force
 · USPTO record
In forceUSPTO record
US 12,269,884Antibody Specifically Binding to ICAM-1 and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,905,331Antibody binding specifically to CD40 and use thereof
In force
 · USPTO record
In forceUSPTO record
US 12,091,457Use for preventing and treating myeloid-derived suppressor cell-related diseases
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 6: 3 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited